Arthritis and Inflammation - Provinal Omega 7

  • Posted by a hidden member.
    Log in to view his profile

    Jun 27, 2017 5:12 PM GMT
    Omega-7 Protects Against Metabolic Syndrome
    By Carol Stockton

    Palmitoleic Acid Improves Arterial Health

    Omega-7’s ability to raise HDL and lower LDL—while also supporting endothelial function—make it extremely beneficial for cardiovascular health.

    Studies show that omega-7 improves lipid balance by favorably regulating fat production within fat cells, while regulating fat burning.2 That means less fat deposition—and lower levels of fat and triglycerides in blood and liver tissue.3,25

    In a lab study done at the Cleveland Clinic, omega-7 supplementation increased beneficial HDL after just 8 to 12 weeks (something statin drugs are not very good at doing).5,26,27 In the same study, the reduction in the size of atherosclerotic plaque in the aorta was 47% lower in the group receiving omega-7 supplementation.5
    Omega-7 levels have also been shown to be powerful predictors of the all-important endothelial function, the control of blood flow and pressure by the inner lining, or endothelium, of blood vessels.28
    These beneficial effects on cholesterol were demonstrated by a study using macadamia nuts and sea buckthorn, two substances that are known for their high omega-7 content. Studies show that after just three weeks of eating macadamia nuts every day, healthy young women had reductions in total and LDL cholesterol, body weight, and body mass index (BMI).29 And in men with high cholesterol, 1 to 3 ounces per day of these fat-containing nuts produced reductions in atherosclerosis risk factors such as markers of inflammation and oxidative stress.30
    These studies may have shown greater effects had the subjects used a purified omega-7 palmitoleic acid supplement instead of the high-fat macadamia nuts, which are also rich in dangerous palmitic acid.

    In a study of patients with stubbornly high lipid levels, a purified omega-7 supplement (840 mg/day) produced modest lipid reductions. LDL fell by 7.6% (from 118 to 109 mg/dL) while non-HDL cholesterol* was reduced by 8.2% (from 147 to 135 mg/dL).6 Patients with the highest levels of baseline triglycerides saw their total cholesterol and triglyceride levels drop by as much as 30%.6
    * (Non-HDL cholesterol is gaining increasing importance as a risk marker for cardiovascular outcomes.6 It is calculated as total cholesterol minus HDL cholesterol.)

    What makes that study remarkable is that most participants were already taking statin or fibrate drugs, yet still had high lipid levels.25 This showed that adding omega-7 to these drugs produced additional benefits, lowering cholesterol and triglycerides where prescription drugs couldn’t.
    In a subsequent controlled clinical trial, patients taking purified omega-7 palmitoleic acid at a lower dose (210 mg/day) had improvements in lipid levels after 30 days of supplementation: triglycerides dropped by 36.9 mg/dL (17%), LDL by 13.5 mg/dL (11%), and beneficial HDL rose by 4.5 mg/dL (10%).7

    Omega-7 Helps Manage Body Weight

    The reason central or abdominal obesity (“apple shape”) is a factor in metabolic syndrome is because it has such strong associations with cardiovascular disease risk.31 This is due, in large part, to the increased inflammation produced by fat tissue.17-19
    Omega-7s help manage this factor of metabolic syndrome because they signal your body to stop storing fat.2,3
    Animals fed diets rich in omega-7 show significant increases in stomach and intestinal hormones that promote the feeling of fullness (satiety).13 At the same time, such diets produce decreases in hunger-promoting hormones.32 The combined effect is a significant reduction in food intake.
    Several statin drugs, while lowering cholesterol and triglycerides, also produce increases in body and liver fat deposition.33 Omega-7s do just the opposite. Omega-7 reduces the production of fat in the liver.3 Increases in liver fat can result in non-alcoholic fatty liver disease (NAFLD), which is considered a major manifestation of the metabolic syndrome—and which can eventually lead to liver failure and even cancer.34

    Research has shown that omega-7 has beneficial effects on a majority of the pathological components of metabolic syndrome.
    It improves insulin sensitivity, lowers LDL-cholesterol-triglycerides, and raises beneficial HDL.3,5,22,24,29 It helps manage body weight by promoting fullness-inducing hormones and dissipating hunger-producing hormones.13,32 Perhaps most important of all, omega-7 acts in a unique fashion to stop the inflammation that forms the link between the metabolic syndrome and its life-shortening consequences.3,21
    By beneficially influencing these deadly pathological factors, omega-7 can dramatically improve cardiovascular and metabolic health.
    If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

    Cao H, Hotamisligil G, Inventors; President and Fellows of Harvard College, Cambridge, MA, assignee. Fatty acid C16: 1N7-Palmitoleate a lipokine and biomarker for metabolic status. September 1, 2011.
    Burns TA, Duckett SK, Pratt SL, Jenkins TC. Supplemental palmitoleic (C16:1 cis-9) acid reduces lipogenesis and desaturation in bovine adipocyte cultures. J Anim Sci. 2012 Oct;90(10):3433-41.
    Yang ZH, Miyahara H, Hatanaka A. Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis. 2011;10:120.
    Stefan N, Kantartzis K, Celebi N, et al. Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care. 2010 Feb;33(2):405-7.
    Experimental Animal Laboratory. Final report for study onCCO Technologies Oil (CCO-Oil) on the development of atherosclerosis: Department of Cardiovascular Medicine, Cleveland Clinic; 2008.
    Green JA. Effect of two levels of Provinal™ (purified Palmitoleic Acid; C16:1n7; Omega 7) on serum lipid and C-reactive protein(CRP) profiles in humans. Tersus Pharmaceuticals, LLC: 2012.
    Martinez L. Provinal (R) in the reduction of CRP: A double blinded, randomized, placebo controlled study. Provinal purified omega 7. Vol: Tersus Pharmaceuticals; 2013.
    Marcus AO. Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. Diabetes Technol Ther. 2000 Spring;2(1):101-10.
    Available at: Accessed January 24, 2014.
    Nestel P, Clifton P, Noakes M. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. J Lipid Res. 1994 Apr;35(4):656-62.
    Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002 Aug;61(3):345-58.
    Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008 Sep 19;134(6):933-44.
    Yang ZH, Takeo J, Katayama M. Oral administration of omega-7 palmitoleic acid induces satiety and the release of appetite-related hormones in male rats. Appetite. 2013 Jun;65:1-7.
    Burns TA, Kadegowda AK, Duckett SK, Pratt SL, Jenkins TC. Palmitoleic (16:1 cis-9) and cis-vaccenic (18:1 cis-11) acid alter lipogenesis in bovine adipocyte cultures. Lipids. 2012 Dec;47(12):1143-53.
    Available at: Accessed January 24, 2014.
    Available at: Accessed January 8, 2014.
    Available at: Accessed January 8, 2014.
    Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 Jul 4;102(1):42-7.
    Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin re
  • Posted by a hidden member.
    Log in to view his profile

    Jun 27, 2017 5:19 PM GMT
    By William Faloon (2009)
    We recognize the medical establishment is agonizingly slow at grasping new concepts. They do wake up to scientific reality, however, when they smell an opportunity to earn tens of billions of dollars.
    Life Extension members were warned long ago about the dangers of excess C-reactive protein in the blood. C-reactive protein is a marker of inflammation. Chronic inflammation, as evidenced by high C-reactive protein blood levels, is a cause of atherosclerosis.1-3 Published studies indicate that elevated C-reactive protein may be a greater risk factor than high cholesterol in predicting heart attack and especially stroke risk.4-8
    There are many natural methods to lower C-reactive protein. The pharmaceutical industry favors using statin drugs: an unnatural way to reduce C-reactive protein. While statin drugs are prescribed to lower LDL (low-density lipoprotein) and total cholesterol, statin drugs also reduce heart attack and stroke risk by suppressing C-reactive protein.
    A clinical study was sponsored by a pharmaceutical company to see if its patented statin drug (Crestor®) would reduce heart attack and stroke risk if given to people with moderate LDL levels, but excess C-reactive protein. The results revealed a 43% reduction in various types of vascular disease after less than two years.9
    These data are impressive on the surface, but the study exposed a harsh reality that we at Life Extension have voiced alarming concern about for decades. As you will read, Crestor® significantly reduced heart attack-stroke incidence, but there were still a startling number of heart attacks and strokes in people whose LDL levels plummeted to extremely low levels. While this study may be used to aggressively promote Crestor®, it exposes the limitations of statin drugs in preventing heart disease and stroke.
  • Posted by a hidden member.
    Log in to view his profile

    Jun 27, 2017 5:20 PM GMT

    C-Reactive Protein Not Lowered Enough
    Despite the very high dose of Crestor® used, median C-reactive protein levels fell only from 4.25 mg/L to 2.2 mg/L of blood. The optimal range for C-reactive protein is under 0.55 mg/L in men and under 1.5 mg/L in women.12 Crestor®, even at the relatively high dose used, fell far short of reducing C-reactive protein enough to completely eliminate this inflammatory marker as a vascular disease risk factor.

    What this high dose of Crestor® did do is lower LDL from a baseline average of 108 to 55 mg/dL at the end of the study. Few statin drug studies have suppressed LDL this much. Please remember that LDL is not all bad. LDL is essential to transport cholesterol from the liver to cells that need it throughout the body. Without sufficient LDL, people will die. The problem is that no one yet knows for sure what truly optimal LDL levels are. You need enough LDL to ensure that sufficient cholesterol is delivered to the cell membranes, but not so much LDL that arterial occlusion manifests.
    We believe that the 43% reduction in risk of major cardiovascular events (including heart attack, stroke, unstable angina, arterial revascularization, and death from cardiovascular causes) observed in this study was a result of suppressing both LDL and C-reactive protein levels, along with other endothelial benefits that statin drugs possess (which can also be obtained by using natural approaches). We are concerned, however, about the long-term effects of using a potent dose of a drug like Crestor®, when safer and more natural strategies are available.
  • Posted by a hidden member.
    Log in to view his profile

    Jun 27, 2017 5:22 PM GMT

    The biological challenge in overweight people is to combat the excess C-reactive protein made directly by fat cells (adipocytes) and the C-reactive protein made in the liver in response to excess amounts of interleukin-6 expressed in abdominal fat that is dumped directly into the liver.
    Since obese and overweight individuals spew out C-reactive protein from their liver and fat cells, it is often challenging to bring this lethal inflammatory compound (C-reactive protein) into safe ranges.
    While we are impressed with the data from the Crestor® study showing the reduction in C-reactive protein and major cardiovascular events, our decade-long evaluation of C-reactive protein blood results prompts us to warn that it will require more than statin drugs to suppress the dangerously high C-reactive protein levels prevalent in so many individuals.
    The good news is that low-cost nutrients and hormones, along with dietary changes, can work as well as statins in reducing deadly C-reactive protein.

    Vitamin C Reduces C-Reactive Protein

    Right after the media put Crestor® on the front pages, a study was published showing that 1,000 mg a day of vitamin C reduces C-reactive protein as well as some statin drugs.14 Needless to say, this vitamin C study received scant media coverage.
    In this University of California at Berkeley study, participants who received vitamin C and started out with C-reactive protein levels greater than 2.00 mg/L had 34% lower levels compared with the placebo group after only two months.14,15
    This study was done based on previous findings that vitamin C supplements reduce elevated C-reactive protein. It would have been interesting to see if the addition of 1,000 mg a day of vitamin C would have reduced the number of “major cardiovascular events” that occurred in the Crestor® study.